The MAA was submitted to the EMA by Mitsubishi Tanabe Pharma GmbH under the centralized procedure, which applies to all member states of the European Union (EU), Iceland, Norway and Liechtenstein. All ...

Mitsubishi Tanabe Pharma is being sold to Bain Capital for about $3.3 billion. Eisai expects a Leqembi "expansion phase" on the horizon. And more. 1. Astellas shifts investment focus to later ...

Bain Capital, an investment firm that has spread its life sciences bets mainly across companies developing novel new medicines, is acquiring Mitsubishi Tanabe Pharma Corporation in a multi-billion ...

Tanabe Mitsubishi Pharma, to U.S. private equity firm Bain Capital, according to Reuters on Friday. The transaction is valued at 510 billion yen, or approximately $3.36 billion. The move is part ...

Mitsubishi is developing a new Pajero Sport, the current generation of which is sold as the Montero Sport in some markets Sales of the midsize SUV are expected to start in 2026, though a U.S ...

Indian drugmakers earn a significant share of revenue from the U.S., the largest importer of Indian pharma products. India's pharma exports to the country stood at $8.73 billion in fiscal 2024 - a ...

Then came the threats of tariffs that the Indian pharma sector could face in the United States. How turbulent could the after-effects be of the possible tariffs? “The key strength of Indian ...

Note :Financial Information is based on numbers. Note :Financial Information is based on numbers. Note :Financial Information is based on numbers. Note :Financial ...

Though Mitsubishi had long used the name in overseas markets, the Lancer badge arrived in the U.S. for the 2002 model year on a compact sedan that competed with the Ford Focus, Honda Civic and ...

The Mitsubishi Montero was a boxy, off-road-oriented SUV that was sold in the U.S. from 1983-2006. The core vehicle had a longer lifespan in other global markets, where it was marketed as the Pajero.

As one of the world’s biggest contributors to climate change, pharma is morally obliged to adapt its processes and operations – and doing so will open up new opportunities for growth.

Last month, Mitsubishi made headlines for reportedly not being very interested in participating in the now-dead merger between Nissan and Honda. When I first heard this, my hand hit my forehead.